{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:57:50Z","timestamp":1772639870504,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04184-z","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:23:19Z","timestamp":1759998199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma"],"prefix":"10.1007","volume":"74","author":[{"given":"Xiangqi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjian","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengpei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"10360","key":"4184_CR1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G et al (2022) Hepatocellular carcinoma [J]. Lancet 400(10360):1345\u20131362","journal-title":"Lancet"},{"issue":"20","key":"4184_CR2","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma [J]. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"7","key":"4184_CR3","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.22.00620","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, Chen Z, Fang W et al (2023) Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial [J]. J Clin Oncol 41(7):1434\u20131443","journal-title":"J Clin Oncol"},{"issue":"10474","key":"4184_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y et al (2025) Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 405(10474):203\u2013215","journal-title":"Lancet"},{"issue":"1","key":"4184_CR5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M et al (2022) Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions [J]. Mol Cancer 21(1):28","journal-title":"Mol Cancer"},{"issue":"11","key":"4184_CR6","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor MH, Lee CH, Makker V et al (2020) Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors [J]. J Clin Oncol 38(11):1154\u20131163","journal-title":"J Clin Oncol"},{"issue":"4","key":"4184_CR7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD (2020) Acquired resistance to immune checkpoint inhibitors [J]. Cancer Cell 37(4):443\u2013455","journal-title":"Cancer Cell"},{"key":"4184_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","author":"HM Kluger","year":"2020","unstructured":"Kluger HM, Tawbi HA, Ascierto ML et al (2020) Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000398","journal-title":"J Immunother Cancer"},{"key":"4184_CR9","doi-asserted-by":"crossref","unstructured":"HUANG Q, WANG W, GE Q, et al (2025) NEK7 induced phosphorylation of EGFR on serine 1070 drive the acquired lenvatinib resistance in hepatocellular carcinoma [J]. Hepatology","DOI":"10.1097\/HEP.0000000000001474"},{"issue":"4","key":"4184_CR10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cac2.12414","volume":"43","author":"JW Eun","year":"2023","unstructured":"Eun JW, Yoon JH, Ahn HR et al (2023) Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun 43(4):455\u2013479","journal-title":"Cancer Commun"},{"issue":"7869","key":"4184_CR11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin H, Shi Y, Lv Y et al (2021) EGFR activation limits the response of liver cancer to lenvatinib [J]. Nature 595(7869):730\u2013734","journal-title":"Nature"},{"issue":"2","key":"4184_CR12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D et al (2024) Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer [J]. Cancer Cell 42(2):209\u201324.e9","journal-title":"Cancer Cell"},{"issue":"4","key":"4184_CR13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N et al (2023) The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients [J]. Cancer Cell 41(4):711\u201325.e6","journal-title":"Cancer Cell"},{"issue":"10","key":"4184_CR14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jamaoncol.2020.2169","volume":"6","author":"P Ravi","year":"2020","unstructured":"Ravi P, Mantia C, Su C et al (2020) Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma [J]. JAMA Oncol 6(10):1606\u20131610","journal-title":"JAMA Oncol"},{"issue":"7","key":"4184_CR15","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/1759-7714.13483","volume":"11","author":"S Kitagawa","year":"2020","unstructured":"Kitagawa S, Hakozaki T, Kitadai R et al (2020) Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review [J]. Thorac Cancer 11(7):1927\u20131933","journal-title":"Thorac Cancer"},{"issue":"4","key":"4184_CR16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA et al (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy [J]. Cell 168(4):707\u2013723","journal-title":"Cell"},{"issue":"3","key":"4184_CR17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.4637","volume":"5","author":"N Zhuo","year":"2022","unstructured":"Zhuo N, Liu C, Zhang Q et al (2022) Characteristics and prognosis of acquired resistance to immune checkpoint inhibitors in gastrointestinal cancer. JAMA Netw Open 5(3):e224637","journal-title":"JAMA Netw Open"},{"issue":"15_suppl","key":"4184_CR18","volume":"38","author":"H-C Sun","year":"2020","unstructured":"Sun H-C, Zhu X-D, Huang C et al (2020) Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: a real-world study. J Clin Oncol 38(15_suppl):e16610-e","journal-title":"J Clin Oncol"},{"issue":"2","key":"4184_CR19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"4184_CR20","volume":"559","author":"L Wang","year":"2023","unstructured":"Wang L, Yang Q, Zhou Q et al (2023) METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett 559:216122","journal-title":"Cancer Lett"},{"issue":"11","key":"4184_CR21","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.7150\/ijbs.69969","volume":"18","author":"S Huang","year":"2022","unstructured":"Huang S, Ma Z, Zhou Q et al (2022) Genome-wide CRISPR\/Cas9 library screening identified that DUSP4 deficiency induces lenvatinib resistance in hepatocellular carcinoma [J]. Int J Biol Sci 18(11):4357\u20134371","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4184_CR22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41420-021-00747-y","volume":"7","author":"Y Lu","year":"2021","unstructured":"Lu Y, Shen H, Huang W et al (2021) Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance [j]. Cell Death Discov 7(1):359","journal-title":"Cell Death Discov"},{"key":"4184_CR23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115489","volume":"210","author":"T Fang","year":"2023","unstructured":"Fang T, Jiao Z, You Y et al (2023) Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1. Biochem Pharmacol 210:115489","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"4184_CR24","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/cas.15719","volume":"114","author":"Z Mei","year":"2023","unstructured":"Mei Z, Gao X, Pan C et al (2023) Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1(+) CD8(+) T cells in HCC via blocking VEGFR2. Cancer Sci 114(4):1284\u20131296","journal-title":"Cancer Sci"},{"issue":"6","key":"4184_CR25","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH et al (2018) Successful Anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12 [J]. Immunity 49(6):1148\u201361.e7","journal-title":"Immunity"},{"issue":"2","key":"4184_CR26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ccell.2025.01.001","volume":"43","author":"X Guo","year":"2025","unstructured":"Guo X, Nie H, Zhang W et al (2025) Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer [J]. Cancer Cell 43(2):248\u201368.e9","journal-title":"Cancer Cell"},{"key":"4184_CR27","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108111","volume":"236","author":"DR Principe","year":"2022","unstructured":"Principe DR, Kamath SD, Korc M et al (2022) The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther 236:108111","journal-title":"Pharmacol Ther"},{"issue":"10391","key":"4184_CR28","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865","journal-title":"Lancet"},{"issue":"11","key":"4184_CR29","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang Z, Wu J et al (2025) A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer [J]. Cell 188(11):3081\u201396.e19","journal-title":"Cell"},{"issue":"4","key":"4184_CR30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang YJ, Piha-Paul SA et al (2019) T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028 [J]. J Clin Oncol 37(4):318\u2013327","journal-title":"J Clin Oncol"},{"issue":"6230","key":"4184_CR31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124\u2013128","journal-title":"Science"},{"issue":"1","key":"4184_CR32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccell.2023.11.010","volume":"42","author":"Y Sun","year":"2024","unstructured":"Sun Y, Wu P, Zhang Z et al (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma [J]. Cancer Cell 42(1):135\u201356.e17","journal-title":"Cancer Cell"},{"issue":"1","key":"4184_CR33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-024-02062-3","volume":"23","author":"DZ Guo","year":"2024","unstructured":"Guo DZ, Zhang X, Zhang SQ et al (2024) Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts [J]. Mol Cancer 23(1):157","journal-title":"Mol Cancer"},{"issue":"3","key":"4184_CR34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/1078-0432.CCR-17-1063","volume":"24","author":"YF Sun","year":"2018","unstructured":"Sun YF, Guo W, Xu Y et al (2018) Circulating tumor cells from different vascular sites exhibit spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical significance in hepatocellular carcinoma. Clin Cancer Res 24(3):547\u2013559","journal-title":"Clin Cancer Res"},{"key":"4184_CR35","doi-asserted-by":"crossref","first-page":"1529016","DOI":"10.3389\/fimmu.2025.1529016","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhang L, Zhao S et al (2025) Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report [J]. Front Immunol 16:1529016","journal-title":"Front Immunol"},{"issue":"1","key":"4184_CR36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/his.14317","volume":"79","author":"A Montasser","year":"2021","unstructured":"Montasser A, BEAUFR\u00e8RE A, Cauchy F et al (2021) Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma [J]. Histopathology 79(1):36\u201346","journal-title":"Histopathology"},{"issue":"9","key":"4184_CR37","doi-asserted-by":"crossref","first-page":"e003311","DOI":"10.1136\/jitc-2021-003311","volume":"9","author":"DJ Pinato","year":"2021","unstructured":"Pinato DJ, Murray SM, Forner A et al (2021) Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy [J]. J Immunother Cancer 9(9):e003311","journal-title":"J Immunother Cancer"},{"issue":"4","key":"4184_CR38","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00262-020-02734-1","volume":"70","author":"K Leuchte","year":"2021","unstructured":"Leuchte K, Staib E, Thelen M et al (2021) Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma [J]. Cancer Immunol Immunother 70(4):893\u2013907","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4184_CR39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3350\/cmh.2020.0095","volume":"27","author":"GS Yoo","year":"2021","unstructured":"Yoo GS, Ahn WG, Kim SY et al (2021) Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: a murine model study [J]. Clin Mol Hepatol 27(1):144\u2013156","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"4184_CR40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-024-01963-5","volume":"9","author":"Q Shan","year":"2024","unstructured":"Shan Q, Yin L, Zhan Q et al (2024) The p-MYH9\/USP22\/HIF-1\u03b1 axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma [J]. Signal Transduct Target Ther 9(1):249","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"4184_CR41","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti B, Lamberti G, Puchala SR et al (2024) Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer [J]. J Clin Oncol 42(11):1311\u20131321","journal-title":"J Clin Oncol"},{"key":"4184_CR42","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1038\/ncomms15440","volume":"8","author":"A Sucker","year":"2017","unstructured":"Sucker A, Zhao F, Pieper N et al (2017) Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions [J]. Nat Commun 8:15440","journal-title":"Nat Commun"},{"issue":"3","key":"4184_CR43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","volume":"168","author":"W Hugo","year":"2017","unstructured":"Hugo W, Zaretsky JM, Sun L et al (2017) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma [J]. Cell 168(3):542","journal-title":"Cell"},{"key":"4184_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.03.018","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang Z, Wu J et al (2025) A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. https:\/\/doi.org\/10.1016\/j.cell.2025.03.018","journal-title":"Cell"},{"issue":"6702","key":"4184_CR45","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew D, Marmarelis ME, Foley C et al (2024) Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384(6702):eadf1329","journal-title":"Science"},{"issue":"17","key":"4184_CR46","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1158\/1078-0432.CCR-22-0657","volume":"28","author":"AJ Schoenfeld","year":"2022","unstructured":"Schoenfeld AJ, Rizvi HA, Memon D et al (2022) Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer. Clin Cancer Res 28(17):3797\u20133803","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4184_CR47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2024.03.003","volume":"81","author":"SH Choi","year":"2024","unstructured":"Choi SH, Lee BM, Kim J et al (2024) Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: a phase II study. J Hepatol 81(1):84\u201392","journal-title":"J Hepatol"},{"issue":"5","key":"4184_CR48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000536549","volume":"13","author":"TH Liu","year":"2024","unstructured":"Liu TH, Chen SC, Rau KM et al (2024) Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression [J]. Liver Cancer 13(5):509\u2013521","journal-title":"Liver Cancer"},{"issue":"8","key":"4184_CR49","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00262-021-03132-x","volume":"71","author":"AM Czarnecka","year":"2022","unstructured":"Czarnecka AM, Sobczuk P, Rogala P et al (2022) Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence [J]. Cancer Immunol Immunother 71(8):1949\u20131958","journal-title":"Cancer Immunol Immunother"},{"issue":"20","key":"4184_CR50","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","volume":"82","author":"B Hu","year":"2022","unstructured":"Hu B, Zou T, Qin W et al (2022) Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma. Cancer Res 82(20):3845\u20133857","journal-title":"Cancer Res"},{"issue":"4","key":"4184_CR51","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH et al (2024) Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses [J]. Nat Med 30(4):1023\u20131034","journal-title":"Nat Med"},{"issue":"28","key":"4184_CR52","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1080\/14796694.2024.2355863","volume":"20","author":"S Badhrinarayanan","year":"2024","unstructured":"Badhrinarayanan S, Cotter C, Zhu H et al (2024) IMbrave152\/SKYSCRAPER-14: a phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma. Future Oncol 20(28):2049\u20132057","journal-title":"Future Oncol"},{"issue":"11","key":"4184_CR53","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-24-0177","volume":"30","author":"DJ Pinato","year":"2024","unstructured":"Pinato DJ, D\u2019alessio A, Fulgenzi CAM et al (2024) Safety and preliminary efficacy of pembrolizumab following transarterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study. Clin Cancer Res 30(11):2433\u20132443","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4184_CR54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000543994","volume":"14","author":"M Piao","year":"2025","unstructured":"Piao M, Li C, Huang Z et al (2025) Conversion surgery after immune checkpoint inhibitor-based combination therapy for initially unresectable hepatocellular carcinoma: a retrospective cohort study [J]. Liver Cancer 14(4):456\u2013473","journal-title":"Liver Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04184-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T17:20:06Z","timestamp":1763054406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04184-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4184"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04184-z","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki, and was approved by the Institutional Review Board of Peking Union Medical College Hospital (IRB No. JS-1391). All patients provided written informed consent before receiving combined target\/ICI antibody treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"331"}}